drugset / Trial / NCT00309322

Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures

NCT00309322

Phase 2 Completed 150 enrolled Novalar Pharmaceuticals, Inc.
RandomizedSingle-groupSingle-blindTreatment

Summary

This Phase 2 clinical study is designed as a multicenter, randomized, blinded, controlled study to evaluate the safety and efficacy of NV-101 in approximately 150 children 4 to 11 years of age. NV-101 or sham injection is administered at the completion of a dental procedure requiring local anesthesia with 2% lidocaine with 1:100,000 epinephrine. The dental procedure(s) shall be performed in a single quadrant of the mouth and include cavity preparation, restoration/filling, teeth cleaning (non-surgical scaling and/or root planing), or crowns.

Timeline

Start
2006-03
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentolamine Small molecule Other

Indications

No indication recorded.